SEC Company Response from Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Jan 31, 2020
Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: Jan. 31, 2020 · CIK: 0001596812 · Accession: 0001213900-20-002282
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36578
Letter
January 31, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ameen Hamady
Jeanne Baker
Re: Enlivex Therapeutics Ltd.
Form 20-F for the year ended December 31, 2018
Filed on April 30, 2019
Form 20-F/A for the year ended December 31, 2018
Filed on January 23,
File No. 001-36578
Ladies and Gentlemen:
On behalf of Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex” or the “Company”), the following response is to the comment letter, dated January 27, 2020 (the “Comment Letter”), concerning the above referenced Form 20-F filed on April 30, 2019, as amended by the Form 20-F/A filed on January 23, 2020 (the “Form 20-F”). Set forth below is the Company’s response to the comment of the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”) contained in the Comment Letter.
In the response below, references to “we”, “our” and “us” refer to the Company. We have reproduced the text of the Staff’s comment in bold-face, followed by the Company’s response. Concurrently with this response, the Company is filing with the SEC Amendment No. 2 to the Form 20-F (the “Amendment”, and the 20-F as amended by the Amendment, the “Amended 20-F”), which incorporates revisions to the Form 20-F.
Item 15. Controls and Procedures, page
1. In light of the fact that the Company amended its Form 20-F for the fiscal year ended December 31, 2018 to include the required disclosures and financial statements of Bioblast Pharma Ltd (Bioblast), please tell us how you concluded that Bioblast’s disclosure controls and procedures and internal controls over financial reporting were effective as of December 31, 2018. Please advise or revise your conclusions accordingly.
The Company’s Response:
Further to discussions with the Staff, the Amendment amends Item 15 of the Amended 20-F in response to the Staff’s comment.
* * *
If you or any other member of the Staff should have any further comments or questions regarding this response, please contact the Company’s outside counsel, Robert L. Grossman, Esq. at (305) 579-0756 or Drew M. Altman, Esq. at (305) 579-0589, each of Greenberg Traurig, P.A.
Sincerely,
Enlivex Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
January 31, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ameen Hamady
Jeanne Baker
Re: Enlivex Therapeutics Ltd.
Form 20-F for the year
ended December 31, 2018
Filed on April 30, 2019
Form 20-F/A for the year
ended December 31, 2018
Filed on January 23,
2020
File No. 001-36578
Ladies and Gentlemen:
On behalf of Enlivex Therapeutics
Ltd., a company organized under the laws of the State of Israel (“Enlivex” or the “Company”),
the following response is to the comment letter, dated January 27, 2020 (the “Comment Letter”), concerning the
above referenced Form 20-F filed on April 30, 2019, as amended by the Form 20-F/A filed on January 23, 2020 (the “Form
20-F”). Set forth below is the Company’s response to the comment of the staff (the “Staff”)
of the Securities and Exchange Commission (the “SEC”) contained in the Comment Letter.
In the response below,
references to “we”, “our” and “us” refer to the Company. We have reproduced the text of the
Staff’s comment in bold-face, followed by the Company’s response. Concurrently
with this response, the Company is filing with the SEC Amendment No. 2 to the Form 20-F (the “Amendment”, and
the 20-F as amended by the Amendment, the “Amended 20-F”), which incorporates revisions to the Form 20-F.
Item 15. Controls and Procedures, page
64
1. In light of the fact that the Company amended its Form 20-F for the fiscal year ended December
31, 2018 to include the required disclosures and financial statements of Bioblast Pharma Ltd (Bioblast), please tell us how you
concluded that Bioblast’s disclosure controls and procedures and internal controls over financial reporting were effective
as of December 31, 2018. Please advise or revise your conclusions accordingly.
The Company’s Response:
Further
to discussions with the Staff, the Amendment amends Item 15 of the Amended 20-F in response to the Staff’s comment.
* * *
If you or any other member
of the Staff should have any further comments or questions regarding this response, please contact the Company’s outside
counsel, Robert L. Grossman, Esq. at (305) 579-0756 or Drew M. Altman, Esq. at (305) 579-0589, each of Greenberg Traurig, P.A.
Sincerely,
Enlivex Therapeutics Ltd.
/s/ Shachar Schlosberger
Shachar Schlosberger
Chief Financial Officer
cc:
Robert L. Grossman
Drew M. Altman
Greenberg Traurig, P.A.